Crossmark

Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity

Published Online: 2015-11-24

Published Print: 2015-12

Authors

Chlebowski, R. T.

Haque, R.

Hedlin, H.

Col, N.

Paskett, E.

Manson, J. E.

Kubo, J. T.

Johnson, K. C.

Wactawski-Wende, J.

Pan, K.

Anderson, G.
Funding

Funding for this research was provided by:

Kaiser Foundation Research Institute (13RHAqu-02-UCLA)
License Information

Text and Data Mining valid from 2015-11-24

Document is current